Protagonist Therapeutics, Inc. Common Stock PTGX
i
Market dataready · fetched 2026-11-13T02:55:31.631Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:01.415218324Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-13T02:51:21.258110+00:00
Protagonist Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 119.00 | 105.1% | 12.9% | |||
| 25Δ | 148.26 | 91.7% | 12.7% | 124.56 | 79.8% | 8.7% |
| 30Δ | 142.26 | 70.6% | 8.2% | |||
| 35Δ | 139.12 | 59.0% | 5.9% | 130.61 | 45.8% | 4.0% |
| 40Δ | 137.30 | 53.1% | 4.7% | 131.70 | 43.6% | 3.4% |
| 45Δ | 135.48 | 47.2% | 3.6% | 132.79 | 41.3% | 2.8% |
| 50Δ | 134.13 | 45.9% | 3.0% | 133.88 | 39.1% | 2.3% |
| 55Δ | 132.96 | 46.2% | 2.6% | 134.97 | 36.8% | 1.7% |
| 60Δ | 131.78 | 46.5% | 2.2% | 135.98 | 36.5% | 1.5% |
| 65Δ | 130.60 | 46.8% | 1.8% | 136.99 | 36.1% | 1.2% |
| 70Δ | 129.16 | 47.9% | 1.5% | 138.00 | 35.8% | 1.0% |
| 75Δ | 127.43 | 49.9% | 1.2% | 139.01 | 35.4% | 0.7% |
| 80Δ | 125.71 | 51.8% | 1.0% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 119.00
- IV
- 105.1%
- B/E move
- 12.9%
25Δ
- Pseudo strike
- 148.26
- IV
- 91.7%
- B/E move
- 12.7%
- Pseudo strike
- 124.56
- IV
- 79.8%
- B/E move
- 8.7%
30Δ
- Pseudo strike
- 142.26
- IV
- 70.6%
- B/E move
- 8.2%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 139.12
- IV
- 59.0%
- B/E move
- 5.9%
- Pseudo strike
- 130.61
- IV
- 45.8%
- B/E move
- 4.0%
40Δ
- Pseudo strike
- 137.30
- IV
- 53.1%
- B/E move
- 4.7%
- Pseudo strike
- 131.70
- IV
- 43.6%
- B/E move
- 3.4%
45Δ
- Pseudo strike
- 135.48
- IV
- 47.2%
- B/E move
- 3.6%
- Pseudo strike
- 132.79
- IV
- 41.3%
- B/E move
- 2.8%
50Δ
- Pseudo strike
- 134.13
- IV
- 45.9%
- B/E move
- 3.0%
- Pseudo strike
- 133.88
- IV
- 39.1%
- B/E move
- 2.3%
55Δ
- Pseudo strike
- 132.96
- IV
- 46.2%
- B/E move
- 2.6%
- Pseudo strike
- 134.97
- IV
- 36.8%
- B/E move
- 1.7%
60Δ
- Pseudo strike
- 131.78
- IV
- 46.5%
- B/E move
- 2.2%
- Pseudo strike
- 135.98
- IV
- 36.5%
- B/E move
- 1.5%
65Δ
- Pseudo strike
- 130.60
- IV
- 46.8%
- B/E move
- 1.8%
- Pseudo strike
- 136.99
- IV
- 36.1%
- B/E move
- 1.2%
70Δ
- Pseudo strike
- 129.16
- IV
- 47.9%
- B/E move
- 1.5%
- Pseudo strike
- 138.00
- IV
- 35.8%
- B/E move
- 1.0%
75Δ
- Pseudo strike
- 127.43
- IV
- 49.9%
- B/E move
- 1.2%
- Pseudo strike
- 139.01
- IV
- 35.4%
- B/E move
- 0.7%
80Δ
- Pseudo strike
- 125.71
- IV
- 51.8%
- B/E move
- 1.0%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 39.43% | |
| 39.82% | |
| 39.94% | |
| 41.06% | |
| 41.15% | |
| 41.29% | |
| 40.99% | |
| 40.37% | |
| 40.03% | |
| 41.69% |
Biotechnology
PVLA
Palvella Therapeutics, Inc. is an innovative biotechnology firm dedicated to developing transformative therapies for rare genetic disorders resulting from specific gene mutations.…
More →PYPD
Description unavailable
More →PYXS
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating…
More →QTTB
Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune response optimization.…
More →QURE
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in…
More →RANI
Rani Therapeutics Holdings Inc. is an innovative biotechnology company transforming the landscape of drug delivery with its proprietary RaniPill™ technology, which enables the…
More →